Dry eye is far more than occasional irritation. For many people it is a chronic condition that affects concentration, work, and quality of life every single day. The good news is that it responds well to the right treatment.
Dry eye disease occurs when the eyes don’t produce enough tears, or when the tears that are produced evaporate too quickly or are of poor quality. The result is an unstable tear film that cannot protect and lubricate the eye surface properly. This causes a spectrum of symptoms ranging from mild grittiness and occasional discomfort to significant pain, blurred vision, and difficulty with screen work, reading, and driving. Dry eye disease is one of the most common conditions seen in eye clinics worldwide, and it is substantially undertreated. Most people assume the symptoms are just something they have to live with. They don’t.
What You Need to Know About Dry Eye Disease
- Dry eye comes in two main forms: aqueous deficient (not enough tears produced) and evaporative (tears evaporate too quickly due to meibomian gland dysfunction) Specialist management is provided by the cornea and refractive surgery subspecialty.
- Evaporative dry eye is by far the more common form, accounting for around 85 percent of cases
- Watery eyes are a very common symptom of dry eye, not a sign that you have enough tears. The irritated surface triggers reflex tearing
- Blepharitis and meibomian gland dysfunction are closely linked to dry eye and often need treating at the same time
- Screen use, contact lens wear, certain medications, and low-humidity environments all make dry eye considerably worse
- Treatment is ongoing rather than curative. The goal is to manage symptoms and protect the ocular surface long-term
Understanding the Tear Film
A healthy tear film is not simply water. It is a precisely structured three-layer coating that covers the entire eye surface and is renewed with every blink.
The outer lipid layer, produced by the meibomian glands in the eyelids, acts as a seal that slows evaporation of the watery layer beneath it. When the meibomian glands are blocked or inflamed, this lipid layer becomes deficient, and the tear film evaporates much faster than it should. That is evaporative dry eye, and it is the most common mechanism behind the condition.
The middle aqueous layer, produced by the lacrimal gland, provides the bulk of tear volume and delivers oxygen and nutrients to the corneal surface. The inner mucin layer, secreted by goblet cells on the conjunctiva, anchors tears to the eye and allows them to spread evenly with each blink. Damage to any of these three layers disrupts the whole system.
Types and Causes
- Lacrimal gland produces insufficient tears
- Around 15 percent of dry eye cases
- Associated with Sjogren’s syndrome and autoimmune disease
- Also caused by lacrimal gland damage or aging
- Symptoms often more severe and persistent
- Treated with intensive lubrication and sometimes punctal plugs
- Tears evaporate faster than normal due to poor lipid layer
- Around 85 percent of dry eye cases
- Driven by meibomian gland dysfunction and blepharitis
- Worsened by screen use, low humidity, and contact lenses
- Symptoms fluctuate and are often worse in the afternoon
- Treated with warm compresses, lid hygiene, and lipid drops
What makes it worse
Screen use reduces blink rate by around 50 percent, dramatically increasing evaporation. Air conditioning, heating, and low-humidity environments accelerate it further. Contact lens wear disrupts the tear film and is a common cause of symptomatic dry eye in younger patients. A long list of medications can reduce tear production or alter tear composition, including antihistamines, antidepressants, beta-blockers, diuretics, and isotretinoin. Hormonal changes, particularly around the menopause, raise dry eye risk sharply in women. Refractive surgery including LASIK can cause dry eye by disrupting the corneal nerves that regulate tear production.
Symptoms
The most common complaints are a gritty, scratchy, or sandy sensation (often worst on waking), burning or stinging in the eyes, redness, blurred vision that fluctuates with blinking, sensitivity to wind and air conditioning, and watery or runny eyes, particularly in cold conditions.
That last one surprises people every time. When the eye surface is dry and irritated, the lacrimal gland produces a flood of reflex tears. These are thin and watery, missing the mucin and lipid components of a normal stable tear film. They run down the cheek but they don’t actually fix the dryness. The eye remains uncomfortable. Treating the underlying dry eye is what stops the watering.
Diagnosis
Dry eye is diagnosed through a combination of patient history and clinical tests. The ophthalmologist assesses tear film break-up time, measures tear volume with the Schirmer test, and examines the ocular surface with staining drops that highlight damaged areas on the cornea and conjunctiva. The eyelid margins and meibomian gland openings are examined to assess the degree of meibomian gland dysfunction. Meibography, an infrared imaging technique that shows meibomian gland structure, is available in specialist clinics and helps identify gland dropout that may be driving chronic evaporative dry eye.
Treatment
Treatment depends on the type and severity of dry eye and usually involves several steps working together. The realistic goal is effective long-term management rather than a permanent cure, though many patients achieve excellent symptom control with the right approach.
OCT imaging can assess the ocular surface) into their eye to treat dry eye disease symptoms” style=”width:100%;border-radius:0.75rem;display:block;” />
Lubricating eye drops
Preservative-free artificial tears are the foundation of treatment for almost all dry eye patients. Used regularly throughout the day, not just when symptoms feel severe, they supplement the deficient tear film and protect the corneal surface. Drops with a lipid or oil component are particularly helpful in evaporative dry eye. Thicker gels or ointments at night provide sustained lubrication while the blink rate is zero.
Warm compresses and lid hygiene
For evaporative dry eye driven by meibomian gland dysfunction, warm compresses applied to the closed lids for five to ten minutes soften the thickened gland secretions and improve their flow. Lid scrubs following the compress reduce debris around the gland openings. Done consistently once or twice daily, this treats the source of the problem rather than just the symptom. The blepharitis page covers technique in detail.
Anti-inflammatory treatment
Dry eye involves a cycle of ocular surface inflammation that perpetuates and worsens the condition beyond the original cause. Cyclosporin drops (Restasis, Ikervis) and lifitegrast (Xiidra) break this cycle when lubricants alone are insufficient. A short course of low-potency steroid drops helps during severe flares. Omega-3 fatty acid supplements support meibomian gland function and reduce inflammation from within.
Advanced treatments
Punctal plugs are tiny silicone plugs inserted into the tear drainage channels to keep tears on the eye surface longer. Thermal pulsation therapy (LipiFlow) applies controlled heat and pressure to the eyelids to clear blocked meibomian glands more thoroughly than home treatment can achieve. Intense pulsed light (IPL) therapy reduces inflammation around the glands. Autologous serum drops, made from the patient’s own blood, are used in severe or treatment-resistant cases.
Lifestyle Changes That Make a Real Difference
Dry eye is one of those conditions where daily habits make a real difference. Not the only treatment, but genuinely part of it.
During screen use, make a conscious effort to blink fully and regularly. Position your screen slightly below eye level so the eye opening is smaller and the surface less exposed. The 20-20-20 rule: every 20 minutes, look at something 20 feet away for 20 seconds. In air-conditioned or heated environments, a desktop humidifier makes a real difference. Wraparound glasses or moisture chamber spectacles help in windy or dry outdoor conditions.
For contact lens wearers, daily disposables cause less tear film disruption than reusable lenses. Reducing daily wear time and using rewetting drops during the day both reduce the burden on the tear film. If lens wear stays persistently uncomfortable despite these adjustments, a trial period in glasses often reveals how much the lenses are contributing, and that information is useful for what comes next.
See Your Ophthalmologist If
- Symptoms are badly affecting work, reading, or daily activities despite using drops regularly
- You have pain rather than just discomfort in one or both eyes
- Vision is blurred in a way that doesn’t clear with blinking or drops
- You have a red, light-sensitive eye alongside dry eye symptoms
- You’re using over-the-counter drops very frequently and still not getting adequate relief
Dry eye that isn’t adequately controlled can damage the corneal surface over time. Persistent symptoms despite basic treatment deserve a proper assessment rather than simply increasing the dose of the same drops. A specialist can identify whether there is an underlying cause being missed and offer treatments beyond what is available over the counter.
Frequently Asked Questions About Dry Eye Disease
-
My eyes water constantly. How can they be dry?
This confuses almost everyone. When the eye surface is irritated by poor tear film quality, the lacrimal gland floods the eye with reflex tears. These are watery and thin, missing the mucin and lipid components needed for a stable tear film. They run down the cheek but don’t actually fix anything. Treating the underlying dry eye reduces the watering in most patients.
-
Which eye drops should I use?
For most patients with evaporative dry eye, drops that contain a lipid or oil component alongside the aqueous base work better than purely watery drops. Preservative-free formulations matter if you’re using drops more than four times a day, as preservatives can damage the ocular surface with frequent use. Not all drops are equal, and the most heavily advertised product isn’t always the most suitable one. Your ophthalmologist or optometrist can guide you toward the right formulation for your specific type.
-
Will dry eye ever go away?
For most people: no. Dry eye caused by meibomian gland dysfunction doesn’t resolve permanently — it’s managed, not cured. That said, some patients whose dry eye has a specific reversible cause (a particular medication, contact lens intolerance) do see real improvement when the trigger is removed. Either way, well-managed dry eye has minimal impact on daily life. The difference between treated and untreated dry eye can be substantial.
-
Can dry eye damage my vision permanently?
In most cases of mild to moderate dry eye, no. The blurring is temporary and improves with blinking or drops. In severe or long-standing untreated dry eye, the corneal surface can develop persistent epithelial damage or scarring that affects vision more lastingly. This is relatively uncommon with appropriate treatment, but it is one reason why persistent symptoms should be assessed properly rather than managed indefinitely with over-the-counter drops.
-
Does diet affect dry eye?
To a meaningful degree, yes. Omega-3 fatty acids found in oily fish and in supplement form have the best evidence for supporting meibomian gland function. Not a magic fix. But it contributes. Staying well hydrated throughout the day supports overall tear production. These aren’t replacements for drops and lid hygiene, but they contribute to the bigger picture.
-
Can I wear contact lenses if I have dry eye?
Many people with dry eye wear contact lenses successfully with the right adjustments. Daily disposable silicone hydrogel lenses tend to be best tolerated. Using rewetting drops during the day and reducing wear time help. If lens wear stays genuinely uncomfortable despite these measures, a trial period wearing glasses only often reveals how much the lenses are contributing to symptoms and helps guide the next step.
If you would like to learn more, the American Academy of Ophthalmology’s dry eye page offers a clear overview of dry eye symptoms, causes, diagnosis, and treatment options.
Dry eye disease (DED) is a multifactorial disease of the ocular surface and tear film characterized by loss of tear film homeostasis, accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation, neural sensitization, and neurosensory abnormalities play etiological roles. The TFOS DEWS II (2017) definition superseded the earlier evaporative/aqueous-deficient binary model, reflecting the understanding that most DED involves overlapping mechanisms. Prevalence estimates range from 5-50% globally depending on diagnostic criteria; symptomatic DED significant enough to affect quality of life affects approximately 10-20% of adults. Meibomian gland dysfunction (MGD) is the most common cause of evaporative DED and the most common overall DED subtype. Diagnosis requires both symptom assessment and objective tear film and ocular surface testing , symptoms alone or signs alone are insufficient for diagnosis or treatment monitoring.
Clinical Overview: Dry Eye Disease
- TFOS DEWS II classification: Aqueous deficient DED (ADDE) , Sjögren syndrome, non-Sjögren lacrimal gland dysfunction; Evaporative DED , MGD (most common), lid abnormalities, reduced blink rate; Mixed , the majority of clinical cases combine both mechanisms
- Symptom assessment: OSDI (Ocular Surface Disease Index, 12 questions) or DEQ-5 (5 questions). OSDI ≥13 = mild DED; ≥23 = moderate; ≥33 = severe. SPEED score is an alternative for MGD-predominant disease.
- Objective signs: TBUT (tear break-up time) , normal above 10 seconds; TBUT below 5 seconds is consistent with DED. Fluorescein staining (cornea), lissamine green staining (conjunctiva/lid margin). Schirmer’s I (without anesthesia): below 5 mm at 5 minutes = aqueous deficiency; 5-10 mm is borderline.
- MGD assessment: Lid margin morphology, meibum quality on expression (liquid, inspissated, toothpaste-like), meibography (OCT or non-contact IR imaging of gland dropout). MGD grade correlates with symptom severity and predicts treatment response.
- Stepwise management: Lid hygiene + lubricants (step 1) → add preservative-free lubricants, omega-3, environment modification (step 2) → add cyclosporine A, lifitegrast, serum tears, punctal occlusion (step 3) → add topical corticosteroids (short course), autologous serum, scleral lenses (step 4)
- Sjögren syndrome: Suspect in bilateral severe ADDE, especially in middle-aged women with dry mouth, joint symptoms, or fatigue. Check anti-SSA (Ro) and anti-SSB (La) antibodies. Rheumatology referral for systemic management.
Pathophysiology
The OCT and the tear film are a complex structure comprising three interdependent layers: the outer lipid layer (produced by meibomian glands, stabilizes the film and reduces evaporation), the aqueous layer (produced by lacrimal glands, provides volume and antimicrobial proteins), and the mucin layer (produced by conjunctival goblet cells, anchors the tear film to the ocular surface glycocalyx). DED results when any of these components fail , through reduced production, increased evaporation, or altered composition.
The vicious circle of DED: Tear film instability leads to hyperosmolarity. Hyperosmolarity activates mitogen-activated protein kinase (MAPK) signaling pathways in epithelial cells, triggering release of inflammatory cytokines (IL-1, IL-6, TNF-alpha, MMP-9). Inflammation damages goblet cells (reducing mucin production) and lacrimal functional units (reducing aqueous secretion), worsening tear film instability. Peripheral and central sensitization of corneal nociceptors amplifies symptom perception , which is why symptoms often persist even when signs improve with treatment.
MGD pathophysiology: Obstruction of meibomian gland orifices from hyperkeratinization of the duct epithelium, combined with increased viscosity of meibum (from altered lipid composition), impairs lipid delivery to the tear film. Inadequate lipid layer allows excessive evaporation, reducing TBUT and causing surface desiccation. Stagnant meibum supports bacterial overgrowth (Staphylococcus, Cutibacterium acnes), which produces lipases that degrade meibum components and generate toxic free fatty acids contributing to lid margin inflammation.
Diagnosis
Clinical evaluation sequence: Symptom questionnaire (OSDI or DEQ-5) before instilling any drops. Non-invasive TBUT (NIBUT) via topographer or instrument, or fluorescein TBUT. Slit-lamp with fluorescein: corneal epithelial staining pattern (interpalpebral staining in evaporative DED; inferior staining in lagophthalmos or exposure). Lissamine green: conjunctival and lid margin staining. Meibomian gland expression: digital pressure or Meibomian Gland Evaluator, scoring meibum quality. Schirmer’s I (without anesthesia, Schirmer’s II with) for aqueous production. Osmolarity measurement (TearLab): above 308 mOsm/L or inter-eye difference above 8 mOsm/L is diagnostic.
MMP-9 point-of-care test (InflammaDry): Detects MMP-9 (matrix metalloproteinase 9) in tear fluid. Positive above 40 ng/mL , indicates active ocular surface inflammation. Positive InflammaDry in a patient with moderate-severe DED symptoms supports escalation to anti-inflammatory therapy (cyclosporine A, lifitegrast) rather than continuing lubricant-only management.
Management: Stepwise Approach
Step 1 , lid hygiene and lubricants: Warm compresses (40-45°C for 4-8 minutes, twice daily) soften inspissated meibum; lid massage expresses treated meibum. Dedicated heated eye masks (MGDRx EyeBag, Blephasteam) are more effective than DIY warm flannels. Lid cleansing removes biofilm and excess lid margin bacteria. Lubricant eye drops: carboxymethylcellulose (CMC), sodium hyaluronate (HA), carbomer gels, polyethylene glycol combinations. Preservative-free formulations for frequent use (>4×/day) or contact lens wearers. Lipid-containing drops (Systane Balance, Evolve, Soothe XP) preferred in MGD.
Step 2 , escalation of lubricants, omega-3, environment: Omega-3 fatty acid supplementation (EPA+DHA 2-3 g/day) reduces meibum viscosity and inflammation , DREAM trial (2018): no significant difference from placebo for primary outcome, but subgroup analyses show modest benefit in MGD. Prescribe preservative-free drops. Humidity modification, screen break habits. Intense pulsed light (IPL) therapy for MGD: photobiomodulation and thermal effect on lid margins, reduces Demodex and bacterial load. Multiple sessions required. Good evidence for symptom and sign improvement in moderate-severe MGD. Thermal pulsation (LipiFlow): applies heat and pressure to inner eyelid surfaces, mechanically expressing meibomian glands; single treatment with evidence for 1-year improvement.
Step 3 , anti-inflammatory therapy: Cyclosporine A 0.05% (Restasis) or 0.1% (Ikervis) , calcineurin inhibitor reducing T-cell-mediated ocular surface inflammation. Takes 3-6 months for full effect; patients often abandon treatment prematurely. Lifitegrast 5% (Xiidra) , LFA-1 antagonist blocking T-cell trafficking; symptom improvement typically faster (4-12 weeks). Autologous serum eye drops (ASED) 20-100% concentration: contain EGF, TGF-beta, fibronectin, and substance P that support epithelial health. Indicated for severe DED, Sjögren syndrome, graft-versus-host disease (GVHD) associated DED, and neurotrophic keratopathy. Punctal occlusion: silicone plugs in lower (and sometimes upper) puncta reduce tear drainage, increasing tear volume. Effective in ADDE. Not appropriate in active inflammation (retains inflammatory mediators as well as tears).
Step 4 , advanced therapies: Short-course topical corticosteroids (loteprednol 0.5%, fluorometholone 0.1%) for acute flares of ocular surface inflammation. Scleral contact lenses: vault the corneal surface, creating a fluid reservoir; significant for severe DED and neurotrophic keratopathy. Amniotic membrane transplantation (ProKera ring) for severe persistent epithelial defects.
Special Populations
Post-refractive surgery DED: LASIK severs corneal nerves, reducing blink reflex and corneal sensation for up to 2 years. Patients should be screened for pre-existing DED before refractive surgery (OSDI score, TBUT, meibography) , moderate-severe DED is a relative contraindication. PRK (photorefractive keratectomy) has lower DED risk than LASIK as it does not create a corneal flap. Post-LASIK DED is managed with aggressive lubricants, punctal occlusion, and cyclosporine; autologous serum if severe.
GVHD-associated DED: Chronic GVHD following hematopoietic stem cell transplantation causes severe bilateral DED through lacrimal gland destruction and goblet cell loss. Often the most debilitating manifestation. Aggressive combination therapy required , topical corticosteroids, cyclosporine, autologous serum, scleral lenses. Work with the transplant team.
Neuropathic ocular pain: A subset of patients report severe DED symptoms with minimal objective signs. Central sensitization of trigeminal pain pathways produces allodynia and hyperalgesia. Management requires distinguishing corneal nerve dysfunction (corneal confocal microscopy may show reduced sub-basal nerve density) from central sensitization. Systemic neuromodulators (gabapentin, low-dose naltrexone, duloxetine) may be appropriate in severe neuropathic cases , a liaison with pain medicine.
Clinical Decision Points
- Moderate DED symptoms, TBUT 4 seconds, positive InflammaDry: Escalate to anti-inflammatory therapy , cyclosporine A or lifitegrast , rather than continuing lubricant-only management. Counsel the 3-6 month lag to effect for cyclosporine.
- Severe symptoms, minimal signs: Consider neuropathic ocular pain. Check corneal sensitivity (esthesiometry). Corneal confocal microscopy if available. Referral to specialist DED clinic or pain medicine if standard treatment fails repeatedly.
- Bilateral severe ADDE, middle-aged woman, dry mouth: Screen for Sjögren syndrome (anti-SSA/SSB, rheumatology referral). Sjögren DED requires aggressive lubricants, serum tears, and systemic immunosuppression coordinated with rheumatology.
- DED before refractive surgery: Treat and control before proceeding. LASIK should not be performed in active moderate-severe DED , it reliably worsens it. PRK or SMILE are preferred alternatives if surgery is indicated.
When to Escalate Urgently
- Persistent epithelial defect not healing despite treatment , risk of corneal ulcer and perforation in severe DED
- Sudden worsening in Sjögren syndrome patient , may reflect new lacrimal gland involvement or systemic flare
- Neurotrophic keratopathy (reduced corneal sensation + non-healing epithelial defect) , requires cenegermin (recombinant human nerve growth factor, Oxervate) and specialist management
Neurotrophic keratopathy is a spectrum from punctate epithelial erosions to frank corneal ulceration and perforation in patients with severely reduced corneal sensation (from herpetic disease, diabetes, post-surgical, or congenital causes). It is not standard DED and does not respond to standard DED treatment. Corneal sensitivity testing at every visit in high-risk patients identifies this before ulceration develops.
Clinical Pearls: Dry Eye Disease
-
Symptoms and signs correlate poorly in DED. You cannot use one without the other.
The TFOS DEWS II data confirmed a weak correlation between symptom scores (OSDI) and objective signs (TBUT, staining, Schirmer’s). Some patients with severe symptoms have minimal signs (neuropathic pain); others with extensive staining and reduced TBUT are surprisingly asymptomatic (reduced corneal sensitivity). Treating only symptoms or only signs leads to incorrect treatment choices. The diagnosis of DED requires both , and treatment decisions should reflect the full clinical picture, not just the one metric that is easiest to measure.
-
Cyclosporine A works , but patients stop it before it does. Counsel the timeline explicitly.
The therapeutic effect of cyclosporine A depends on reversing T-cell-mediated chronic inflammation, which takes 3-6 months of consistent twice-daily use. Most patients expect drop-like symptom relief within days and discontinue the treatment well before benefit accrues. At the prescribing visit, state explicitly: “This medication takes 3-6 months to work. You will not feel better from it in the first few weeks. That is normal. Keep using it.” The burning sensation from the preservative in Restasis is a common early complaint , switching to Ikervis (cyclosporine 0.1% in cationic emulsion, better tolerated) or prescribing preservative-free formulations helps adherence.
-
IPL therapy for MGD is now supported by good evidence. It is not a luxury treatment.
Intense pulsed light (IPL) was initially used for rosacea and adopted for MGD based on the observation that rosacea patients’ eye symptoms improved after facial IPL. Multiple RCTs now show significant improvements in TBUT, meibum quality, and OSDI at 3 months with a course of 3-4 sessions. The mechanism includes thermal effects on meibomian glands, photobiomodulation of inflammation, and direct reduction of Demodex and abnormal telangiectatic lid vessels. For moderate-severe MGD refractory to lid hygiene and lubricants, IPL is a clinically justified step , not an upsell.
Further reading: TFOS DEWS II Report , the definitive evidence-based DED consensus document. For the ocular surface context, see blepharitis (closely linked to MGD) and keratoconus (where DED management is important pre- and post-CXL). Specialist context: cornea and refractive surgery subspecialty page.